Cue Biopharma
49 hedge funds and large institutions have $10.4M invested in Cue Biopharma in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
49
Holders Change
-6
Holders Change %
-10.91%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
13
Closed
13
Calls
$20K
Puts
$6K
Net Calls
+$14K
Net Calls Change
-$25K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
$2.11M |
| 2 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
$69.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
$632K |
| 4 |
Renaissance Technologies
New York
|
$33.7K |
| 5 |
Squarepoint
New York
|
$31.7K |
Top Sellers
| 1 |
GLA
Good Life Advisors
Reading,
Pennsylvania
|
$0 |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
$297K |
| 3 |
Millennium Management
New York
|
$0 |
| 4 |
Jane Street
New York
|
$0 |
| 5 |
HF
HRT Financial
New York
|
$0 |
